Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
about
Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and BiomarkersThe Immunogenetics of Autoimmune CholestasisIL-17A blockade or deficiency does not affect progressive renal fibrosis following renal ischaemia reperfusion injury in mice.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Liver Illness and Psoriatic Patients.
P2860
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
@en
type
label
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
@en
prefLabel
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
@en
P2860
P50
P921
P356
P1476
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases
@en
P2093
Haiyan Zhang
P2860
P304
P356
10.1155/2015/436450
P5008
P577
2015-06-04T00:00:00Z